Redeye initiates coverage of Integrum, a uniquely positioned orthopedic company intensifying the commercialization of its bone-anchored prosthetic implant for amputees. Strong tailwinds from its recent FDA (PMA) approval – which gives it the niche to itself for some years – and a promising US partnership should ramp up sales growth in the coming years as Integrum harvests its substantial but underappreciated potential.